Can Exenatide Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Research Design/Plan: After screening, each subject will receive 1 measurements of EGP with
prime-continuous Infusion of 3-3H-glucose. After completing the EGP measurement each subject
will receive a Double Tracer OGTT.
Methods: Visit 1: Screening. Medical history will be obtained, physical exam performed, and
pregnancy test performed.
Visit 2: Endogenous Glucose Production Measurement: The rate of EGP will be measured with
3-3H-glucose.
Visit 3: Double Tracer OGTT
Phase:
Phase 4
Details
Lead Sponsor:
Ralph DeFronzo The University of Texas Health Science Center at San Antonio
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)